ArticleFrontiers in neurology2026
Temporal and disproportionality analysis of vaccine-associated Guillain-Barré syndrome: a 21-year VAERS study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Guillain-Barré syndrome (GBS) remains a critical vaccine safety concern. We conducted a comprehensive pharmacovigilance analysis of 21-year VAERS data to identify vaccine-GBS disproportionality signals and temporal patterns. Methods: We analyzed 9,755,435 VAERS reports (2004-2024) including 2,216 GBS cases using four disproportionality algorithms (ROR, PRR, IC, EBGM). Time-to-onset was compared between 1,534 GBS and 120,763 non-GBS events using Kaplan-Meier analysis. Results: Twenty-six vaccines met all four algorithm criteria, predominantly influenza formulations (19/26; RORs 2.4-8.5), validating historical surveillance observations. Novel signals emerged for both RSV vaccines (Arexvy ROR 3.01, Abrysvo ROR 6.82) and zoster vaccine (ROR 3.01), consistent with post-marketing estimates of 3-9 excess cases per million doses. COVID-19 vaccines showed no concordant signals despite established Janssen associations, reflecting denominator dilution from 7.89 million COVID-19 reports (81% of the database). GBS exhibited characteristic delayed onset-median 13 days (IQR 5-29) versus 0 days for non-GBS events ( Conclusion: Multiple vaccines showed disproportionate GBS reporting signals with delayed temporal patterns consistent with biological plausibility; because these derive from passive surveillance, they are hypothesis-generating and do not establish causality. Despite rare associations, absolute risks (1-9 per million doses) are far outweighed by disease prevention benefits, supporting current vaccination policies with ongoing surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.